Coronary Embolism in Atrial Fibrillation: A Distinct High‐Risk Phenotype With Residual Thromboembolic Risk Despite Anticoagulation
Journal of the American Heart Association · 05.05.2026 · 15 (9)
DOI: 10.1161/jaha.125.045749 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 05.05.2026. Verfasst von Jinsong Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology The First Affiliated Hospital of Ningbo University Ningbo Zhejiang China. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Embolism, Myocardial Infarction. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Coronary embolism (CE) is an underrecognized cause of acute myocardial infarction (AMI) in patients with atrial fibrillation (AF). Dedicated management guidelines are lacking because of limited evidence.
Methods
This retrospective cohort study leveraged routinely collected electronic health records and regional death registry data from a tertiary hospital in China (2014–2023). Among 4777 patients with AMI, CE was diagnosed using a 3‐stage validation process: modified Shibata criteria, blinded angiographic core laboratory assessment, and final adjudication. Patients were categorized into 3 groups: CE with AF (n=78), non‐CE AMI with AF (n=205), and non‐CE AMI without AF (n=3937). Overlap weighting based on propensity scores was used to balance baseline covariates, and weighted Cox proportional hazards models with competing‐risk analysis were applied for comparative outcome analyses.
Results
CE accounted for 1.6% (95% CI, 1.3%–2.0%) of all AMI cases and was present in 14.7% to 27.6% of AF‐related AMI. Compared with non‐CE AMI patients without AF, those with CE and AF had significantly higher risks of all‐cause mortality (overlap‐weighted hazard ratio [HR], 1.77 [95% CI, 1.15–2.71]) and ischemic stroke (overlap‐weighted HR, 4.45 [95% CI, 2.34–8.45]), despite 79.2% receiving therapeutic anticoagulation.
Conclusions
CE complicating AF represents a high‐risk phenotype characterized by high residual thromboembolic risk despite anticoagulation. An integrated management strategy is proposed for future investigation, incorporating multimodal imaging, embolism‐targeted reperfusion, and optimization of antithrombotic therapy, including standard‐dose direct oral anticoagulants. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06845956.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology The First Affiliated Hospital of Ningbo University Ningbo Zhejiang China.
- Ningbo Clinical Guidance Center for Cardiovascular Disease Prevention and Treatment Ningbo Zhejiang China.
- Zhejiang Provincial Key Laboratory of Precision Medicine for Atherosclerotic Diseases Ningbo Zhejiang China.
- Ningbo Clinical Research Center for Cardiovascular Diseases Ningbo Zhejiang China.
ORCID-Profile: Jinsong Cheng, Hengyi Mao, Minfang Guan, Hanbin Cui
Zitieren
APA
Cheng, J., Mao, H., Guan, M., & Cui, H. (2026). Coronary Embolism in Atrial Fibrillation: A Distinct High‐Risk Phenotype With Residual Thromboembolic Risk Despite Anticoagulation. Journal of the American Heart Association, 15(9). https://doi.org/10.1161/jaha.125.045749
Vancouver
Cheng J, Mao H, Guan M, Cui H. Coronary Embolism in Atrial Fibrillation: A Distinct High‐Risk Phenotype With Residual Thromboembolic Risk Despite Anticoagulation. Journal of the American Heart Association. 2026;15(9). doi:10.1161/jaha.125.045749
BibTeX
@article{Cheng2026,
author = {Cheng, Jinsong and Mao, Hengyi and Guan, Minfang and Cui, Hanbin},
title = {Coronary Embolism in Atrial Fibrillation: A Distinct High‐Risk Phenotype With Residual Thromboembolic Risk Despite Anticoagulation},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {9},
doi = {10.1161/jaha.125.045749}
}
EUVIMED